First‐in‐Class Composite Angiotensin Receptor–Neprilysin Inhibitors (ARNI) in Practice

Sacubitril/valsartan, a first‐in‐class angiotensin receptor–neprilysin inhibitor (ARNI) inhibits angiotensin II and neprilysin, enhancing circulating vasoactive peptides. It is recommended in heart failure with reduced ejection fraction (HFrEF) as a result of the PARADIGM‐HF trial. 1 This review discusses the rationale for neprilysin inhibition, data supporting efficacy, and practical tips for patient selection and utilization.